TrialLancet (London, England)2022

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative GroupPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.